Indivior PLC (INDV) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of Indivior PLC stock $18.87, price $26.74, that is 29.4% below the price, quality 73 out of 100. Rating: overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $3.13 – $41.83 · fair‑value band $16.34 – $21.02 · the $26.74 price screens above the $18.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Indivior PLC Ordinary Shares in your weekly email
Every Wednesday you see whether Indivior PLC Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
Show moreShow less
It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026.
Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Stock analysis
Indivior PLC (INDV) currently trades at $26.74, while our model-based Fair Value estimate is $18.87, 29% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $35.20 per share, and 7 of the 12 models we run sit above the $26.74 price.
Bear case: the DCF Models group reads lowest at $10.92, and 5 of the 12 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $16.34 (bear) to $21.02 (bull), the price of $26.74 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 73/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Indivior PLC Ordinary Shares reported revenue of $1.2B in FY2025 versus $791M in FY2021, a compound +11.9%/yr. Reported net income was $210M in FY2025, compounding +0.6%/yr from FY2021.
Key figures
Market cap $3.1B Mid · P/E ratio 7.5 · P/S ratio 2.24 · EPS (TTM) $3.57 · Net margin 32.8% · Return on equity 12.2% · Return on assets (EBIT) 4.5% (5-year average) · Operating margin 54.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 90 out of 100 (low confidence).
What moves the price
The share trades about 36% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −29%, INDV screens richer than that median.
Fair Value models
Bear$16.34Fair Value $18.87Bull$21.02
Price $26.74 · Downside -29.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($3.06 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $107,955, on Aug 27, 2026. Over the same period, 2 people sold shares worth $2.8M.
BuyWoodrow D AndersonChief Accounting Officer2× since Aug 5, 2026: 3,000 shares, avg. $35.99$107,955Aug 27, 2026
SaleChristian HeidbrederChief Scientific Officer2× since Jun 11, 2026: 37,172 shares, avg. $39.60$1.5MJul 10, 202610b5-1 plan
SaleRyan PreblickChief Financial Officer36,000 shares at $37.70$1.4MJun 8, 202610b5-1 plan
BuyBarbara RyanDirector3× since Jan 5, 2026: 814 shares, avg. $35.24$28,685Mar 13, 2026
BuyStuart A KingsleyDirector940 shares at $31.87$29,958Mar 6, 2026
BuyDaniel A NinivaggiDirector775 shares at $35.39$27,427Jan 5, 202610b5-1 plan
BuyMark StejbachDirector775 shares at $35.39$27,427Jan 5, 202610b5-1 plan
BuyDavid E. WheadonDirector1,771 shares at $35.39$62,676Jan 5, 202610b5-1 plan
BuyKeith HumphreysDirector775 shares at $35.39$27,427Jan 5, 202610b5-1 plan
Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+4.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.9%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+11.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.8.2% vs 22.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−24% → 21%
News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: The business draws strength from its expanding flagship treatment in the opioid use disorder market together with merger synergies, yet remains limited by negative equity and free cash flow despite positive net income.
Main risk: Negative equity and ongoing free cash flow strain could limit operational flexibility and hinder sustained investment in the core CNS portfolio.
Indivior is advancing a merger of equals with Supernus that would pool two CNS drug portfolios and deliver substantial cost synergies. Its flagship treatment continues to expand in the opioid use disorder market even as the transaction moves toward a vote. Our models see the shares as overvalued. Does the combined company stand to grow faster through diversification than Indivior would on its own, or will the shift in focus slow its momentum?
Compare Indivior PLC Ordinary Shares with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score73 · Top 25%
Fair Value upside−29.4% · Below median
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets17.4% · Top 25%
Net margin (12 months)32.8% · Top 25%
Operating margin (12 months)54.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)13.4% · Above median
Dividend yield (12 months)0.0% · Bottom 25%
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)7.5× · Cheapest 25%
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months)2.24× · Cheaper than median
EV/EBITDA4.9× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)67· sector 25
PAST (return on equity)0· sector 29
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 32
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
As of Nov 9, 2026, our model estimates a fair value of $18.87 versus a price of $26.74, about 29% lower (overvalued).
What is the fair value of INDV?
Our model-based fair value for Indivior PLC is $18.87 (as of Nov 9, 2026), built from audited fundamentals. The current price: $26.74.
What is the quality score of INDV?
Indivior PLC has a Quality Score of 73/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Indivior PLC (INDV)?
Our model-based price target is the fair value of $18.87 (as of Nov 9, 2026) from 12 valuation models. Cautious scenario $16.34, optimistic scenario $21.02. It is a calculation from audited fundamentals, not an analyst target.
What is the Indivior PLC Ordinary Shares stock forecast for 2026?
Our models put fair value at $18.87, about 29% lower versus a price of $26.74 (overvalued). Cautious scenario $16.34, optimistic scenario $21.02. The calculation is refreshed regularly with new filings.
What is the revenue of Indivior PLC (INDV)?
Indivior PLC reported trailing-twelve-month revenue of about $1.4B (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Indivior PLC (INDV)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Indivior PLC it is $18.87 per share (as of Nov 9, 2026), against a price of $26.74. It is the blended result of 12 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Economic Profit, Growth Earnings).
Is Indivior PLC Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 9, 2026, INDV trades above its calculated fair value: price $26.74, fair value $18.87, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INDV?
No. The price is what the market pays today ($26.74); the fair value is what the company's own numbers justify ($18.87). For Indivior PLC the two are $7.87 per share apart. That gap is exactly why we show both numbers side by side.
How much is Indivior PLC Ordinary Shares worth?
The market values Indivior PLC at about $3.1B (market capitalisation, as of Nov 9, 2026). Per share that is $26.74; our models calculate a fair value of $18.87 per share.
What do the bullish and bearish scenarios say about INDV?
Our models span a range for Indivior PLC: cautious scenario $16.34, base $18.87, optimistic $21.02 per share (as of Nov 9, 2026, price $26.74). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of INDV?
Indivior PLC trades at a price-to-earnings ratio of 7.5 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $18.87 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 10.7 (reported for FY2025: 15.9). Other multiples: P/S 2.2, EV/EBITDA 4.9.
How solid is the balance sheet of Indivior PLC (INDV)?
Balance-sheet figures for Indivior PLC (as of Nov 9, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 73/100, which measures business quality independently of the share price.
How far is INDV from its 52-week high?
Indivior PLC trades at $26.74, about 36% below its 52-week high of $41.83 and at the low of $26.74 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $18.87 is for.
Which stocks are comparable to Indivior PLC Ordinary Shares?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Indivior PLC Ordinary Shares stock attractive at the current price?
The data as of Nov 9, 2026: price $26.74, calculated fair value $18.87 (−29%), Quality Score 73/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INDV calculated?
We run Indivior PLC through 12 models from 5 families: DCF Models, Earnings-Based, Multiples, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $18.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Indivior PLC itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Indivior PLC (INDV)?
The closing price on Nov 5, 2026 was $26.74. Our model-based fair value is $18.87, about 29% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Indivior PLC Ordinary Shares right now?
The price sits above even our optimistic bull case ($21.02). The favourable scenario is already priced in. Solid but not exceptional quality (73/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Indivior PLC
How large is the market capitalisation of Indivior PLC (INDV)?
The market capitalisation of Indivior PLC is $3.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Indivior PLC (INDV)?
The price-to-sales ratio of Indivior PLC is 2.24 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Indivior PLC (INDV)?
Earnings per share at Indivior PLC are $3.57 (price ÷ EPS = P/E 7.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Indivior PLC (INDV)?
The net margin of Indivior PLC is 32.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Indivior PLC (INDV)?
The return on equity (ROE) of Indivior PLC is 12.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Indivior PLC (INDV)?
On an EBIT basis the return on assets of Indivior PLC is 4.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Indivior PLC (INDV)?
The operating margin of Indivior PLC is 54.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Indivior PLC (INDV)?
Revenue at Indivior PLC is growing +13.4% versus a year earlier (3y avg +11.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Indivior PLC (INDV)?
Earnings per share at Indivior PLC are growing +239% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Indivior PLC (INDV) generate?
The free cash flow of Indivior PLC is −$93.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Indivior PLC (INDV) carry?
The net debt of Indivior PLC is $156M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Indivior PLC Ordinary Shares in the live analysis
One click puts Indivior PLC Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026
